Treatment Options for Chemotherapy-Induced Nausea and Vomiting
Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dop...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Stieler, Jens M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2003 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Adis International Limited 2003 |
|---|
| Übergeordnetes Werk: |
Enthalten in: American Journal of Cancer - Springer International Publishing, 2002, 2(2003), 1 vom: Jan., Seite 15-26 |
|---|---|
| Übergeordnetes Werk: |
volume:2 ; year:2003 ; number:1 ; month:01 ; pages:15-26 |
| Links: |
|---|
| DOI / URN: |
10.2165/00024669-200302010-00002 |
|---|
| Katalog-ID: |
SPR035644354 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR035644354 | ||
| 003 | DE-627 | ||
| 005 | 20230519112241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00024669-200302010-00002 |2 doi | |
| 035 | |a (DE-627)SPR035644354 | ||
| 035 | |a (SPR)00024669-200302010-00002-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stieler, Jens M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment Options for Chemotherapy-Induced Nausea and Vomiting |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Adis International Limited 2003 | ||
| 520 | |a Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. | ||
| 650 | 4 | |a Ondansetron |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metoclopramide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cisapride |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Granisetron |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tropisetron |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Reichardt, Peter |4 aut | |
| 700 | 1 | |a Riess, Hanno |4 aut | |
| 700 | 1 | |a Oettle, Helmut |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American Journal of Cancer |d Springer International Publishing, 2002 |g 2(2003), 1 vom: Jan., Seite 15-26 |w (DE-627)SPR035643889 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2003 |g number:1 |g month:01 |g pages:15-26 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00024669-200302010-00002 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2003 |e 1 |c 01 |h 15-26 | ||
| author_variant |
j m s jm jms p r pr h r hr h o ho |
|---|---|
| matchkey_str |
stielerjensmreichardtpeterriesshannooett:2003----:ramnotosoceohrpidcd |
| hierarchy_sort_str |
2003 |
| publishDate |
2003 |
| allfields |
10.2165/00024669-200302010-00002 doi (DE-627)SPR035644354 (SPR)00024669-200302010-00002-e DE-627 ger DE-627 rakwb eng Stieler, Jens M. verfasserin aut Treatment Options for Chemotherapy-Induced Nausea and Vomiting 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 2003 Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. Ondansetron (dpeaa)DE-He213 Metoclopramide (dpeaa)DE-He213 Cisapride (dpeaa)DE-He213 Granisetron (dpeaa)DE-He213 Tropisetron (dpeaa)DE-He213 Reichardt, Peter aut Riess, Hanno aut Oettle, Helmut aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 2(2003), 1 vom: Jan., Seite 15-26 (DE-627)SPR035643889 nnns volume:2 year:2003 number:1 month:01 pages:15-26 https://dx.doi.org/10.2165/00024669-200302010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 2003 1 01 15-26 |
| spelling |
10.2165/00024669-200302010-00002 doi (DE-627)SPR035644354 (SPR)00024669-200302010-00002-e DE-627 ger DE-627 rakwb eng Stieler, Jens M. verfasserin aut Treatment Options for Chemotherapy-Induced Nausea and Vomiting 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 2003 Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. Ondansetron (dpeaa)DE-He213 Metoclopramide (dpeaa)DE-He213 Cisapride (dpeaa)DE-He213 Granisetron (dpeaa)DE-He213 Tropisetron (dpeaa)DE-He213 Reichardt, Peter aut Riess, Hanno aut Oettle, Helmut aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 2(2003), 1 vom: Jan., Seite 15-26 (DE-627)SPR035643889 nnns volume:2 year:2003 number:1 month:01 pages:15-26 https://dx.doi.org/10.2165/00024669-200302010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 2003 1 01 15-26 |
| allfields_unstemmed |
10.2165/00024669-200302010-00002 doi (DE-627)SPR035644354 (SPR)00024669-200302010-00002-e DE-627 ger DE-627 rakwb eng Stieler, Jens M. verfasserin aut Treatment Options for Chemotherapy-Induced Nausea and Vomiting 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 2003 Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. Ondansetron (dpeaa)DE-He213 Metoclopramide (dpeaa)DE-He213 Cisapride (dpeaa)DE-He213 Granisetron (dpeaa)DE-He213 Tropisetron (dpeaa)DE-He213 Reichardt, Peter aut Riess, Hanno aut Oettle, Helmut aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 2(2003), 1 vom: Jan., Seite 15-26 (DE-627)SPR035643889 nnns volume:2 year:2003 number:1 month:01 pages:15-26 https://dx.doi.org/10.2165/00024669-200302010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 2003 1 01 15-26 |
| allfieldsGer |
10.2165/00024669-200302010-00002 doi (DE-627)SPR035644354 (SPR)00024669-200302010-00002-e DE-627 ger DE-627 rakwb eng Stieler, Jens M. verfasserin aut Treatment Options for Chemotherapy-Induced Nausea and Vomiting 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 2003 Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. Ondansetron (dpeaa)DE-He213 Metoclopramide (dpeaa)DE-He213 Cisapride (dpeaa)DE-He213 Granisetron (dpeaa)DE-He213 Tropisetron (dpeaa)DE-He213 Reichardt, Peter aut Riess, Hanno aut Oettle, Helmut aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 2(2003), 1 vom: Jan., Seite 15-26 (DE-627)SPR035643889 nnns volume:2 year:2003 number:1 month:01 pages:15-26 https://dx.doi.org/10.2165/00024669-200302010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 2003 1 01 15-26 |
| allfieldsSound |
10.2165/00024669-200302010-00002 doi (DE-627)SPR035644354 (SPR)00024669-200302010-00002-e DE-627 ger DE-627 rakwb eng Stieler, Jens M. verfasserin aut Treatment Options for Chemotherapy-Induced Nausea and Vomiting 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 2003 Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. Ondansetron (dpeaa)DE-He213 Metoclopramide (dpeaa)DE-He213 Cisapride (dpeaa)DE-He213 Granisetron (dpeaa)DE-He213 Tropisetron (dpeaa)DE-He213 Reichardt, Peter aut Riess, Hanno aut Oettle, Helmut aut Enthalten in American Journal of Cancer Springer International Publishing, 2002 2(2003), 1 vom: Jan., Seite 15-26 (DE-627)SPR035643889 nnns volume:2 year:2003 number:1 month:01 pages:15-26 https://dx.doi.org/10.2165/00024669-200302010-00002 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 2003 1 01 15-26 |
| language |
English |
| source |
Enthalten in American Journal of Cancer 2(2003), 1 vom: Jan., Seite 15-26 volume:2 year:2003 number:1 month:01 pages:15-26 |
| sourceStr |
Enthalten in American Journal of Cancer 2(2003), 1 vom: Jan., Seite 15-26 volume:2 year:2003 number:1 month:01 pages:15-26 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Ondansetron Metoclopramide Cisapride Granisetron Tropisetron |
| isfreeaccess_bool |
false |
| container_title |
American Journal of Cancer |
| authorswithroles_txt_mv |
Stieler, Jens M. @@aut@@ Reichardt, Peter @@aut@@ Riess, Hanno @@aut@@ Oettle, Helmut @@aut@@ |
| publishDateDaySort_date |
2003-01-01T00:00:00Z |
| hierarchy_top_id |
SPR035643889 |
| id |
SPR035644354 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035644354</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112241.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00024669-200302010-00002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035644354</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00024669-200302010-00002-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stieler, Jens M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment Options for Chemotherapy-Induced Nausea and Vomiting</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2003</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Limited 2003</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ondansetron</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metoclopramide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cisapride</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Granisetron</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tropisetron</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reichardt, Peter</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riess, Hanno</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oettle, Helmut</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">American Journal of Cancer</subfield><subfield code="d">Springer International Publishing, 2002</subfield><subfield code="g">2(2003), 1 vom: Jan., Seite 15-26</subfield><subfield code="w">(DE-627)SPR035643889</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:15-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00024669-200302010-00002</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2003</subfield><subfield code="e">1</subfield><subfield code="c">01</subfield><subfield code="h">15-26</subfield></datafield></record></collection>
|
| author |
Stieler, Jens M. |
| spellingShingle |
Stieler, Jens M. misc Ondansetron misc Metoclopramide misc Cisapride misc Granisetron misc Tropisetron Treatment Options for Chemotherapy-Induced Nausea and Vomiting |
| authorStr |
Stieler, Jens M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR035643889 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Treatment Options for Chemotherapy-Induced Nausea and Vomiting Ondansetron (dpeaa)DE-He213 Metoclopramide (dpeaa)DE-He213 Cisapride (dpeaa)DE-He213 Granisetron (dpeaa)DE-He213 Tropisetron (dpeaa)DE-He213 |
| topic |
misc Ondansetron misc Metoclopramide misc Cisapride misc Granisetron misc Tropisetron |
| topic_unstemmed |
misc Ondansetron misc Metoclopramide misc Cisapride misc Granisetron misc Tropisetron |
| topic_browse |
misc Ondansetron misc Metoclopramide misc Cisapride misc Granisetron misc Tropisetron |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
American Journal of Cancer |
| hierarchy_parent_id |
SPR035643889 |
| hierarchy_top_title |
American Journal of Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR035643889 |
| title |
Treatment Options for Chemotherapy-Induced Nausea and Vomiting |
| ctrlnum |
(DE-627)SPR035644354 (SPR)00024669-200302010-00002-e |
| title_full |
Treatment Options for Chemotherapy-Induced Nausea and Vomiting |
| author_sort |
Stieler, Jens M. |
| journal |
American Journal of Cancer |
| journalStr |
American Journal of Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2003 |
| contenttype_str_mv |
txt |
| container_start_page |
15 |
| author_browse |
Stieler, Jens M. Reichardt, Peter Riess, Hanno Oettle, Helmut |
| container_volume |
2 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Stieler, Jens M. |
| doi_str_mv |
10.2165/00024669-200302010-00002 |
| title_sort |
treatment options for chemotherapy-induced nausea and vomiting |
| title_auth |
Treatment Options for Chemotherapy-Induced Nausea and Vomiting |
| abstract |
Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. © Adis International Limited 2003 |
| abstractGer |
Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. © Adis International Limited 2003 |
| abstract_unstemmed |
Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days. © Adis International Limited 2003 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Treatment Options for Chemotherapy-Induced Nausea and Vomiting |
| url |
https://dx.doi.org/10.2165/00024669-200302010-00002 |
| remote_bool |
true |
| author2 |
Reichardt, Peter Riess, Hanno Oettle, Helmut |
| author2Str |
Reichardt, Peter Riess, Hanno Oettle, Helmut |
| ppnlink |
SPR035643889 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00024669-200302010-00002 |
| up_date |
2024-07-03T15:29:24.911Z |
| _version_ |
1803572283883651073 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035644354</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519112241.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00024669-200302010-00002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035644354</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00024669-200302010-00002-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stieler, Jens M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment Options for Chemotherapy-Induced Nausea and Vomiting</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2003</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Limited 2003</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Nausea and emesis are among the most important adverse effects of cytostatic therapy. They can be distinguished between anticipatory, acute and delayed nausea and vomiting. The different mechanisms of action of the current antiemetic drugs, serotonin (5-$ HT_{3} $) receptor antagonists, dopamine antagonists and corticosteroids are reviewed and their efficacy is discussed. The potential benefits of the new antiemetic neurokinin receptor ($ NK_{1} $) antagonists as well as other possible ways to influence emesis and to combine antiemetic drugs are explained. The best control of anticipatory emesis is achieved by adequate control of acute and delayed emesis and nausea from the very start of chemotherapy. At present, the most effective regimen for control of acute emesis is administration of a 5-$ HT_{3} $ receptor antagonist plus a corticosteroid and an $ NK_{1} $ antagonist on day 1. The control of delayed nausea and emesis consists of good control of acute emesis, application of an $ NK_{1} $ antagonist on day 1, possibly supplemented with metoclopramide combined with a corticosteroid on the subsequent days.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ondansetron</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metoclopramide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cisapride</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Granisetron</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tropisetron</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reichardt, Peter</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riess, Hanno</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oettle, Helmut</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">American Journal of Cancer</subfield><subfield code="d">Springer International Publishing, 2002</subfield><subfield code="g">2(2003), 1 vom: Jan., Seite 15-26</subfield><subfield code="w">(DE-627)SPR035643889</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:15-26</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00024669-200302010-00002</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2003</subfield><subfield code="e">1</subfield><subfield code="c">01</subfield><subfield code="h">15-26</subfield></datafield></record></collection>
|
| score |
7.4006386 |